medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2019, Number 4

Next >>

Arch Neurocien 2019; 24 (4)

Clostridioides difficile infection in a Mexico City neurological referral center

Tadeo-Escobar I, Ángeles-Morales V, Soto-Hernandez JL, Cárdenas HGA

Language: Spanish
References: 32
Page: 6-13
PDF size: 402.20 Kb.


ABSTRACT

Background. Clostridioides difficile is an important re-emerging pathogen and the primary cause of nosocomial diarrhea worldwide, particularly in high-income countries.
Aim of study. To present a case series of Clostridioides difficile infection in a neurological referral center.
Methods. Observational, retrospective study to present cases of C. difficile infection (CDI) in a neurological referral center in Mexico City from January 2016 to December 2018.
Results. Sixteen inpatients developed CDI during the period of study. All infected patients received wide-spectrum antimicrobial therapy within six weeks before symptom onset. More than one-half of affected patients were females. Cerebrovascular disease was the main diagnosis on admission, followed by infectious diseases. Other risk factors included the administration of proton pump inhibitors, corticosteroids, and obesity.
Conclusions. Neurological patients are prone to develop CDI because of a conjunction of several risk factors, indeed the concomitant use of corticosteroids, proton pump inhibitors and obesity / diabetes (before the use of extended-spectrum antibiotics). Antibiotic stewardship programs must be enforced to ensure the rational use of antibiotics in order to decrease the risk of CDI.


REFERENCES

  1. Heinlen L, Ballard JD. Clostridium difficile infection. Am J Med Sci. 2010; 340(3):247-52

  2. Wiegand PN, Nathwani D, Wilcox MH, et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systemic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;8(1):1-14

  3. Ma GK, Brensinger CM, Wu Q, et al. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: A cohort study. Ann Intern Med 2017;167(3):152-158

  4. Reigadas Ramirez E, Bouza ES. Economic burden of Clostridium difficile infection in European countries. Adv Exp Med Biol 2018;1050:1-12

  5. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014;69(4):881-891

  6. Abou Chakra CN, Pepin J, Sirard S, et al. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One 2014;9:e98400. doi.10.1371/journal.pone.0098400

  7. McDonald EG, Milligan J, Frenette C, et al. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med 2015; 175:784-791

  8. Bloomfield MG, Sherwin JC, Gkrania-Klotsas E. Risk factors for mortality in Clostridium difficile infection in the general hospital population: a systematic review. J Hosp Infect 2012;82:1-12

  9. Petrosillo N. Tackling the recurrence of Clostridium difficile infection. Med Mal Infect 2018;48(1):18-22

  10. Camacho-Ortiz A, Ponce de Leon A, Sifuentes-Osornio J. Enfermedad asociada a Clostridium difficile en America Latina. Gac Med Mex 2009;145(3):223-229

  11. Ramirez-Rosales A, Cantú-Llanos E. Mortalidad intrahospitalaria en pacientes con diarrea asociada a infección por Clostridium difficile. Rev Gastroenterol Mex 2012;77:60-65

  12. Dávila LP, Garza-Gonzalez E, Rodríguez-Zulueta P, et al. Increasing rates of Clostridium difficile infection in Mexican hospitals. Braz J Infect Dis 2017;21(5):530-534

  13. Morfin-Otero R, Garza-Gonzalez E, García García G, et al. Clostridium difficile infection in patients with chronic kidney disease in Mexico. Clin Nephrol 2018;90:350-356

  14. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108(4):478-498

  15. Clements AC, Magalhães RJ, Tatem AJ, et al. Clostridium difficile PCR rybotype 027: assessing the risk of further worldwide spread. Lancet Infect Dis 2010;10:395-404

  16. Hung YP, Lee JC, Lin HJ, et al. Clinical impact of Clostridium difficile colonization. J Microbiol Immunol Infect. 2015;48(3):241-248

  17. Wijarnpreecha K, Sornprom S, Thongprayoon C, et al. Nasogastric tube and outcomes of Clostridium difficile infection: A systemic review and meta-analysis. J Evid Based Med. 2018:11:40-45

  18. Wijarnpreecha K, Sornprom S, Thongprayoon C, et al. The risk of Clostridium difficile associated diarrhea in nasogastric tube insertion: A systematic review and meta-analysis. Dig Liver Dis. 2016;48(5):468-472.

  19. Banaei N, Anikst V, Schroeder LF. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015; 372(24):2368-2369

  20. Ho J, Dai RZW, Kwong TNY, et al. Disease burden of Clostridium difficile infections in adults Hong Kong, China, 2006-2014. Emerg Infect Dis. 2017;23:1671-1679

  21. Lopardo G, Morfin-Otero R, Moran-Vazquez II, et al. Epidemiology of Clostridium difficile: a hospital-based descriptive study in Argentina and Mexico. Braz J Infect Dis. 2015;19(1):8-14

  22. Dasenbrock HH, Bartolozzi AR, Gormley WB, et al. Clostridium difficile infection after subarachnoid hemorrhage: A Nationwide-Analysis. Neurosurgery. 2016;78:412-420

  23. Tripathy S, Nair Rothburn M. Clostridium difficile associated disease in a neurointensive care unit. Front Neurol. 2013;4:82

  24. Cornely OA, Nathwani D, Ivanescu C, et al. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother. 2014;69:2892-2900

  25. Hefazi M, Patnaik MM, Hogan WJ, et al. Safety and efficacy of fecal microbiota transplant for recurrent Clostridium difficile infection in patients with cancer treated with cytotoxic chemotherapy: A single-Institution retrospective case series. Mayo Clin Proc 2017;92(11):1617-1624

  26. Fischer M, Kao D, Kelly C, et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2016;22:2402-2409

  27. Aroniadis OC, Brandt LJ, Greenberg A, et al. Long-term follow up study on fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: A multicenter experience. J Clin Gastroenterol 2016;50(5):398-402

  28. Konturek PC, Koziel J, Dieterich W, et al. Successful therapy of Clostridium difficile infection with fecal microbiota transplantation. J Physiol Pharmacol. 2016;67(6):859-866

  29. Kelly CR, Jhunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109:1065-1071

  30. Fisher M, Kao D, Mehta SR, et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: A multicenter study. Am J Gastroenterol 2016;111:1024-1031

  31. Meighani A, Hart BR, Mittal C, et al. Predictors of fecal transplant failure. Eur J Gastroenterol Hepatol 2016;28:826-830

  32. Dehlhom-Lambertsen E, Hall BK, Jørgensen SMD, et al. Cost saving following faecal microbiota transplantation for recurrent Clostridium difficile infection. Therap Adv Gastroenterol 2019:12:1756284819843002. doi: 10.1177/1756284819843002




2020     |     www.medigraphic.com